If authorization is granted, the first shots could be administered as early as Dec. 21.
Moderna seeks FDA emergency use authorization for its COVID-19 vaccine. If granted, the first shots could be administered as early as Dec. 21, 2020.
. The data also shared that the vaccine was 100 percent effective at preventing severe cases of coronavirus.According to Moderna, efficacy of the vaccine was consistent across age, race and ethnicity, and gender demographics. The company continues to monitor safety data, but since Nov. 16 when it shared that the only concerns were mild side effects including pain or redness at the injection site, fatigue, fever, muscle and joint pain, and headaches, no new serious safety concerns have been identified.
According to aNew York Timesinterview with Stéphane Bancel, Moderna's chief executive, if authorization is granted, the first shots could be administered as early as Dec. 21. Bancel said the company was"on track" to produce 20 million doses by the end of December and 500 million to a billion in 2021. Since both vaccines require two shots, 20 million doses would be enough for 10 million people.
Moderna is just behind Pfizer and its German partner BioNTech, which over a week ago asked FDA regulators toapprove their COVID-19 vaccine for emergency use in the US. The vaccine also requires two doses per person, and Pfizer said it can produce up to 50 million doses this year with about half going to the United States. headtopics.comRead more: POPSUGAR Fitness »
Biden inauguration live updates: Biden takes over at White House
Updates during the transition from the Trump to Biden administrations -- and about a second Senate impeachment trial.